Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PRISM

- PMLiVE

UCB launches UK product helpline for patients and HCPs

UCBCares will answer treatment queries and use feedback to drive innovation

- PMLiVE

Medical Research Council launches disease compounds research library

Teams up with AZ, GSK, Janssen, Pfizer, Takeda and UCB

- PMLiVE

Merck decision to drop odanacatib lifts UCB/Amgen

Pulls plug on osteoporosis candidate after studies show high risk of stroke

- PMLiVE

Takeda: No decision yet on shutdown of Cambridge, UK unit

Tells PMLiVE that consultation over proposed closure of R&D site still ongoing

- PMLiVE

UCB joins with Atlético Madrid for epilepsy awareness campaign

Spanish football players release video in support of ongoing initiative

- PMLiVE

Amgen and UCB’s romosozumab hits goals in male osteoporosis

Firms will discuss data with regulators before planning a new male licence application

- PMLiVE

Pharma forms Parkinson’s disease trials consortium

Hopes to make clinical trials “smarter” through sharing of past PD trial data

- PMLiVE

Amgen says romosozumab on track for 2016 filing

Reports ‘significant’ reduction of fractures in post-menopausal osteoporosis patients

- PMLiVE

UCB bags FDA approval for epilepsy drug Briviact

Wins US licence as the add-on treatment is launched in Germany and the UK

- PMLiVE

Pascale Richetta moves from AbbVie to UCB

She joins the biopharmaceutical company as executive vice president

- PMLiVE

UCB wins European approval for epilepsy drug Briviact

Plans first launches within weeks

translational pharmacology medicine dose

Study shows R&D returns too low in pharma to be sustainable

Deloitte study shows drop in profit and rise in costs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links